Memantine
- Generic Name
- Memantine
- Brand Names
- Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21N
- CAS Number
- 19982-08-2
- Unique Ingredient Identifier
- W8O17SJF3T
- Background
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...
- Indication
Memantine is used to manage moderate to severe Alzheimer's dementia .
...
- Associated Conditions
- Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
NTS-WBRT in Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT05013892
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)
- Conditions
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- University of New Mexico
- Registration Number
- NCT04966546
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 192
- Registration Number
- NCT04939597
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 69
- Registration Number
- NCT04857983
- Locations
- 🇺🇸
Clinical Teaching Facility (CTF B-403 at UCSD Medical Center), San Diego, California, United States
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
- Conditions
- Interventions
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 200
- Registration Number
- NCT04804644
- Locations
- 🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸Kaiser Permanente-Bellflower, Bellflower, California, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT04801342
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Memantine in Body Focused Repetitive Behaviors
- Conditions
- Interventions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 100
- Registration Number
- NCT04792645
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Bjorn H. Ebdrup
- Target Recruit Count
- 46
- Registration Number
- NCT04789915
- Locations
- 🇩🇰
Centre for Neuropsychiatric Schizophrenia Research, CNSR & Centre for Clinical Intervention & Neuropsychiatric Schizophrenia Research, CINS, Glostrup, Capitol Region, Denmark
The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Mendel AI
- Target Recruit Count
- 60
- Registration Number
- NCT04737967
- Locations
- 🇪🇬
Faculty of Medicine Cairo University - Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine, Cairo, Egypt
Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Universidad Autonoma de San Luis Potosí
- Target Recruit Count
- 33
- Registration Number
- NCT04698525
- Locations
- 🇲🇽
Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosi, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.